Idarubicin Accord

Idarubicin, the active ingredient in Idarubicin Accord, is an anthracycline antibiotic presented as a sterile powder for intravenous infusion for use in adult patients with acute myeloid leukemia and, off‑label, acute lymphoblastic leukemia. It works by intercalating DNA and inhibiting topoisomerase II, leading to cell death in rapidly dividing malignant cells.

GNH USA supplies Idarubicin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Idarubicin is an anthracycline used in the treatment of hematologic malignancies.

Acute Myeloid Leukemia: induces remission by causing DNA strand breaks in leukemic blasts. Acute Lymphoblastic Leukemia (off‑label): may be employed in refractory cases to achieve cytoreduction. Relapsed or refractory acute leukemia: provides an alternative therapeutic option when standard regimens have failed.

Idarubicin is associated with a range of adverse reactions that require monitoring.

Common Side Effects: - Nausea and vomiting - Alopecia (hair loss) - Myelosuppression (decreased blood cell counts) - Fatigue - Mucositis (inflammation of the mouth lining) - Diarrhea

Serious or Rare Side Effects: - Cardiotoxicity (reduced cardiac function) - Severe neutropenia leading to infection - Hemorrhage or bleeding disorders - Secondary malignancies (therapy‑related cancers) - Acute tumor lysis syndrome - Anaphylactic or severe hypersensitivity reactions

When using Idarubicin, clinicians should observe several safety measures.

Cardiac monitoring: baseline and periodic ejection fraction assessment. Hematologic monitoring: weekly complete blood counts. Liver function: evaluate hepatic enzymes before and during therapy. Pregnancy: avoid use unless benefits outweigh potential fetal risks. Drug interactions: avoid concurrent cardiotoxic agents. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicin may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Combination with other anthracyclines: increased risk of cardiotoxicity. - Cardiac glycosides (e.g., digoxin): heightened arrhythmia risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): elevated plasma concentrations.

Moderate Interactions (Monitor Closely): - Myelosuppressive antimicrobials (e.g., linezolid): additive bone‑marrow suppression. - Radiotherapy to the same field: additive tissue injury.